Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Malaria kills more than half a million and affects over 225 million people every year.

ArtemisininFollowing a number of groundbreaking clinical trials, Professor Sir Nick White and his colleagues successfully demonstrated the effectiveness of artemisinin in the treatment of malaria. They also pioneered artemisinin-combination therapy (ACT), the most effective and fast-acting malaria treatment in the world.

Read the full article

Similar stories

Landmark antibody study to test immune responses against COVID-19

Four UK centres will conduct the ‘Stratification of Clinically Vulnerable People for COVID-19 Risk using Antibody Testing (STRAVINSKY)’ study over the next two years, to identify the patient groups most vulnerable to COVID-19.

New partnership to combat deadly pathogens

The Pandemic Sciences Institute and the UK's Defence Science and Technology Laboratory (Dstl) have agreed to jointly study the dangerous pathogens that could cause future pandemics.

Benemérita Universidad Autónoma de Puebla representatives visit Jenner Institute

Academic representatives from Benemérita Universidad Autónoma de Puebla (BUAP), one of the leading universities in Mexico, paid a visit to NDM’s Jenner Institute.

RECOVERY trial team wins the MRC Impact Prize

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Continued support to CPM helps it explore personalised medicine

The Dr Stanley Ho Medical Development Foundation will continue its funding support for The Centre for Personalised Medicine (CPM) for further seven years.

Shifting the needle: finding solutions for rare diseases

Rare diseases are a global health challenge. To address this, organisations around the world, including the Nuffield Department of Medicine (NDM), are working together to find solutions for patients.